AMYPAD is a collaborative research initiative aiming to improve the understanding, diagnosis, and management of Alzheimer’s disease (AD) by using beta-amyloid Positron Emission Tomography (PET) imaging. ADDI is pleased to announce that the data from AMYPAD’s Prognostic and Natural History Study (PNHS) is now permissibly accessible through the AD Workbench.

The AMYPAD PNHS is an open-label, prospective, multi‐center, longitudinal cohort study linked to several ongoing European parent cohorts of preclinical and prodromal individuals. Researchers are trying to understand the role of amyloid imaging in the earliest stages of AD and increase the chances of successful secondary prevention trials.

Amyloid PET imaging can capture the extent of amyloid accumulation and the continued accumulation of amyloid burden beyond the plateau observed in cerebrospinal fluid (CSF). In addition, PET imaging provides information about the topographical distribution in the brain. The potential value of PET quantification in the assessment of amyloid burden, which is needed to facilitate drug intervention is also highlighted in the recent approval of anti-amyloid antibodies by the US Food and Drug Administration.

PNHS recruited individuals with no or minimal cognitive impairment enriched for at risk of AD from 11 European parent cohorts. This includes more than 3,300 patient level records, of which 1,600 have at least one amyloid PET acquisition. Looking ahead, the number of parent cohorts and available data (which may include quantification of advanced MRI sequences, genetics, and blood biomarkers,) will be added to the dataset. For the research community, this dataset can be used to further the understanding of AD at the pre-dementia phase and create opportunities to address current knowledge gaps.

“I think it is amazing that my visit to AMYPAD is contributing to the important research goals of AMYPAD. Contributing to such a large study with all these cohorts makes me feel like my effort will have true effect and this make me very happy!”, said Dhr. V. – a research participant of AMYPAD’s PNHS.

“We are proud to partner with ADDI to help further our understanding of the early stages of AD to accelerate scientific progress. This partnership powers global open access to the project’s data. The PNHS dataset will be maintained and improved over the next years thanks to the close collaboration with ADDI,” said Frederik Barkhof (Amsterdam UMC) and Gill Farrar (GE HealthCare) - AMYPAD Project Coordinators.

For more information about PNHS, you can read the study design paper, “Quantitative amyloid PET in Alzheimer’s disease: the AMYPAD prognostic and natural history study.” Dataset summary details will be posted on AD Connect shortly.

For more information about AMYPAD, please visit: